In Vivo Scientist II
ARTBIONorway12 hours ago
Full-timeResearch, Analyst +1
Track This Job
Add this job to your tracking list to:
- Monitor application status and updates
- Change status (Applied, Interview, Offer, etc.)
- Add personal notes and comments
- Set reminders for follow-ups
- Track your entire application journey
Save This Job
Add this job to your saved collection to:
- Access easily from your saved jobs dashboard
- Review job details later without searching again
- Compare with other saved opportunities
- Keep a collection of interesting positions
- Receive notifications about saved jobs before they expire
AI-Powered Job Summary
Get a concise overview of key job requirements, responsibilities, and qualifications in seconds.
Pro Tip: Use this feature to quickly decide if a job matches your skills before reading the full description.
Summary
We are seeking a Scientist II to join our growing In Vivo-Biology team. We are also open to relocating new colleagues to Oslo! In this role, you will play a key part in advancing our innovative pipeline of targeted radiotherapies designed to revolutionize cancer treatment.
Are you a highly motivated scientist with a passion for in vivo oncology research? Do you thrive in a collaborative environment and enjoy tackling complex scientific challenges? If so, we encourage you to apply!
Key Responsibilities
ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (212Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs with lead program AB001 currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital. For more information, visit www.artbio.com, and follow us on LinkedIn and Twitter.
As an emerging, global biotech with locations in Boston, Massachusetts, Basel, Switzerland, London, England and Oslo, Norway, we take advantage of diverse scientific depth and insights which makes ARTBIO a unique place to work. We are driven by a desire to do better for cancer patients, lowering the burden of toleration and safety while at the same time raising the bar on clinical efficacy and duration.
EEO Statement
ARTBIO is proud to be an equal opportunity workplace and is an affirmative action employer. We are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status. If you have a disability or special need that requires accommodation, please let us know.
ARTBIO does not accept unsolicited resumes from external agencies or recruiters. Submission of a resume without a prior written agreement does not create any express or implied contract between ARTBIO and the agency. ARTBIO will not pay any fees related to unsolicited resumes.
We are seeking a Scientist II to join our growing In Vivo-Biology team. We are also open to relocating new colleagues to Oslo! In this role, you will play a key part in advancing our innovative pipeline of targeted radiotherapies designed to revolutionize cancer treatment.
Are you a highly motivated scientist with a passion for in vivo oncology research? Do you thrive in a collaborative environment and enjoy tackling complex scientific challenges? If so, we encourage you to apply!
Key Responsibilities
- Design, execute, and interpret in vivo studies to evaluate the activity and therapeutic potential of radioligand candidates, and communicate findings through high-quality documentation and presentations
- Partner with CROs, academic collaborators, and industry partners to deliver studies supporting the discovery, characterization, and optimization of radiotherapeutics
- Collaborate effectively across multidisciplinary teams, engaging internal stakeholders to inform strategy and drive data-driven decision making
- Provide scientific and operational leadership for in vivo components of project teams, ensuring seamless planning and execution
- Develop, implement, and maintain laboratory protocols and safety procedures in alignment with regulatory, ethical, and radiation-protection standards
- Remain current with scientific advancements, emerging technologies, and evolving best practices within the radiopharmaceutical and in vivo research fields
- Contribute to the scientific community through authorship of peer-reviewed publications and by representing ARTBIO at conferences via oral or poster presentations
- PhD or equivalent degree in biomedical sciences, pharmacology, radiochemistry, medical physics, or a related discipline
- Demonstrated hands-on experience with small-animal oncology models (mice and rats), supported by certified training in laboratory animal science (FELASA Category C, CAREiN, or equivalent)
- Experience in the evaluation and development of radiopharmaceuticals is highly desirable
- Proven expertise in preclinical biodistribution and efficacy assessments using molecular imaging, ex vivo biodistribution, and related techniques
- Working knowledge of dosimetry is an advantage
- Prior experience managing external collaborations or CRO-based studies is beneficial
- Ability to work independently while contributing effectively to collaborative, multidisciplinary teams
- Exceptional attention to detail, strong interpersonal skills, and excellent organizational and communication capabilities
- A creative, adaptable mindset and enthusiasm for contributing to a fast-paced, agile, small-company environment
ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (212Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs with lead program AB001 currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital. For more information, visit www.artbio.com, and follow us on LinkedIn and Twitter.
As an emerging, global biotech with locations in Boston, Massachusetts, Basel, Switzerland, London, England and Oslo, Norway, we take advantage of diverse scientific depth and insights which makes ARTBIO a unique place to work. We are driven by a desire to do better for cancer patients, lowering the burden of toleration and safety while at the same time raising the bar on clinical efficacy and duration.
EEO Statement
ARTBIO is proud to be an equal opportunity workplace and is an affirmative action employer. We are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status. If you have a disability or special need that requires accommodation, please let us know.
ARTBIO does not accept unsolicited resumes from external agencies or recruiters. Submission of a resume without a prior written agreement does not create any express or implied contract between ARTBIO and the agency. ARTBIO will not pay any fees related to unsolicited resumes.
Key Skills
Ranked by relevanceReady to apply?
Join ARTBIO and take your career to the next level!
Application takes less than 5 minutes